[Prevalence of antiretroviral drug resistance in treatment-naive injecting drug users infected with HIV-1 in Guangzhou, 2008-2015].
PMID: 30744272
2019
Zhonghua liu xing bing xue za zhi
Abstract: The highest mutation rate of E138A was detected in subtype CRF08_BC (3.23%).
High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
PMID: 30891603
2019
The Journal of antimicrobial chemotherapy
Discussion: Furthermore, previous studies evaluating the variability of the IN gene revealed that amino acid variations at codon 138 (E138A/D/K/T) could arise from G-to-A hypermutation resulting from APOBEC-mediated RNA editing, and also from natural polymorphism during viral replication.
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
PMID: 31037930
2019
Revista espanola de quimioterapia
Table: E138A/E
Table: E138A
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
PMID: 31169022
2019
AIDS research and human retroviruses
Abstract: Rilpivirine and etravirine DRMs E138A/Q/R and E138K increased from 4.9% and 0.4% to 9.7% and 1.7%, respectively.
Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Discussion: In respect to that, E138A was also found in our cohort, but was not reported in this study.
Discussion: reported TDR of 12.3% in a cohort of 750 HIV-infected persons diagnosed in northern Italy in the time period 2013-2016, with E138A mutation being the most frequent.
Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.
Result: Positions 140, 143, 148 and 155 (involved in major resistance pathways, are in VG3, as well as position 138, which may display the resistance mutations E138KAT.
Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County.
Abstract: PI and INSTI TDR remained low, with noted E138A prevalence of 2.9%.
Result: The only mutation associated with INSTI resistance was E138A (2.9%).
Result: The presence of E138A, a mutation associated with INSTI resistance, was noted from 2007-2013, however no significant trend was observed (p = 0.74).
Discussion: E138A is an accessory mutation that confers major resistance to RAL an
Discussion: Although there is no indication of a significant, underlying trend, it should be noted that instances of E138A doubled in 2010-2013 compared to 2007-2009, which could be a result of increasing INSTI usage.
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Result: For NNRTIs, the most prevalent drug resistance mutations were K103 N (1.59%), V179D + K103R (1.33%), Y181C (0.80%), V108I (0.53%), Y188L (0.53%), G190A (0.53%), H221Y (0.53%), Y318F (0.53%), A98G (0.27%), V106A (0.27%), E138A (0.27%), E138R (0.27%), Y188C (0.27%) and M230 L (0.27%).
Detection of human immunodeficiency virus Type 1 phylogenetic clusters with multidrug resistance mutations among 2011 to 2017 blood donors from the highly endemic Northern Brazilian Amazon.
HIV mutation literature information.
PMID: 
2019
Zhonghua liu xing bing xue za zhi
Browser Board
Co-occurred Entities
Filtrator
ViMRT